<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Hematol</journal-id><journal-title>Annals of Hematology</journal-title><issn pub-type="ppub">0939-5555</issn><issn pub-type="epub">1432-0584</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17340137</article-id><article-id pub-id-type="publisher-id">269</article-id><article-id pub-id-type="doi">10.1007/s00277-007-0269-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>CD34-related coexpression of <italic>MDR1 and BCRP</italic> indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>van den Heuvel-Eibrink</surname><given-names>Marry M.</given-names></name><address><phone>+31-10-4636691</phone><fax>+31-10-4636801</fax><email>m.vandenheuvel@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van der Holt</surname><given-names>Bronno</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burnett</surname><given-names>Alan K.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Knauf</surname><given-names>Wolfgang U.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fey</surname><given-names>Martin F.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Verhoef</surname><given-names>Gregor E. G.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vellenga</surname><given-names>Edo</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ossenkoppele</surname><given-names>Gert J.</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>L&#x000f6;wenberg</surname><given-names>Bob</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sonneveld</surname><given-names>Pieter</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Hematology, P.O. Erasmus MC, Dr. Molewaterplein 40, 3015 GJ Rotterdam, The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Pediatric Oncology/Hematology, Erasmus MC&#x02013;Sophia Children&#x02019;s Hospital, Rotterdam, The Netherlands </aff><aff id="Aff3"><label>3</label>Department of Trials &#x00026; Statistics&#x02013;HOVON Data Center, Erasmus MC&#x02013;Daniel den Hoed Cancer Center, Rotterdam, The Netherlands </aff><aff id="Aff4"><label>4</label>Wales School of Medicine, Cardiff University, Cardiff, UK </aff><aff id="Aff5"><label>5</label>University Hospital Benjamin Franklin, Berlin, Germany </aff><aff id="Aff6"><label>6</label>Department of Medical Oncology, Inselspital, Bern, Switzerland </aff><aff id="Aff7"><label>7</label>Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium </aff><aff id="Aff8"><label>8</label>Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands </aff><aff id="Aff9"><label>9</label>VU University Medical Center, Amsterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>3</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2007</year></pub-date><volume>86</volume><issue>5</issue><fpage>329</fpage><lpage>337</lpage><history><date date-type="received"><day>4</day><month>12</month><year>2006</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag 2007</copyright-statement></permissions><abstract><p>Clinical resistance to chemotherapy in acute myeloid leukemia (AML) is associated with the expression of the multidrug resistance (MDR) proteins P-glycoprotein, encoded by the <italic>MDR1</italic>/<italic>ABCB1</italic> gene, multidrug resistant-related protein (MRP/ABCC1), the lung resistance-related protein (LRP), or major vault protein (MVP), and the breast cancer resistance protein (BCRP/ABCG2). The clinical value of <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>/<italic>MVP</italic>, and <italic>BCRP</italic> messenger RNA (mRNA) expression was prospectively studied in 154 newly diagnosed AML patients &#x02265;60&#x000a0;years who were treated in a multicenter, randomized phase 3 trial. Expression of <italic>MDR1</italic> and <italic>BCRP</italic> showed a negative whereas <italic>MRP1</italic> and <italic>LRP</italic> showed a positive correlation with high white blood cell count (respectively, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Higher <italic>BCRP</italic> mRNA was associated with secondary AML (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). <italic>MDR1</italic> and <italic>BCRP</italic> mRNA were highly significantly associated (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), as were <italic>MRP1</italic> and <italic>LRP</italic> mRNA (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) expression. Univariate regression analyses revealed that CD34 expression, increasing <italic>MDR1</italic> mRNA as well as <italic>MDR1</italic>/<italic>BCRP</italic> coexpression, were associated with a lower complete response (CR) rate and with worse event-free survival and overall survival. When adjusted for other prognostic actors, only CD34-related <italic>MDR1/BCRP</italic> coexpression remained significantly associated with a lower CR rate (<italic>p</italic>&#x02009;=&#x02009;0.03), thereby identifying a clinically resistant subgroup of elderly AML patients.</p></abstract><kwd-group><title>Keywords</title><kwd><italic>MDR1</italic></kwd><kwd><italic>MRP1</italic></kwd><kwd><italic>LRP</italic></kwd><kwd><italic>BCRP</italic></kwd><kwd>Genes</kwd><kwd>Elderly AML</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2007</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Clinical resistance to chemotherapy in acute myeloid leukemia (AML) is often associated with the expression of (membrane) transport-associated multidrug resistance (MDR) proteins. Expression of P-glycoprotein (P-gp), encoded by the <italic>MDR1</italic> gene, is an independent adverse prognostic factor for response and survival in de novo AML [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Moreover, it has been shown that besides P-gp, also the MDR-related protein (MRP1/ABCC1) and the lung resistance-related protein (LRP), also designated as the major vault protein (MVP), are expressed in AML. However, the prognostic significance of the latter resistance proteins has not been settled [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Some years ago, a new drug resistant protein, i.e., the breast cancer resistance protein (BCRP/ABCG2), which is the equivalent of the mitoxantrone (MXT) resistant protein and the placental ABC transporter (ABCP), was found to be expressed in AML [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. The precise role of either resistance proteins among poor risk AML such as in patients of older age has not been established. This study prospectively investigated the relevance of <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> messenger RNA (mRNA) expression in combination with known prognostic characteristics like CD34 expression, white blood cell (WBC) count, and secondary AML as possible denominators of response and survival in patients with AML aged 60+ who were treated in the same clinical trial.</p></sec><sec id="Sec2" sec-type="methods"><title>Patients and methods</title><sec id="Sec3"><title>Patients</title><p>A group of 154 patients with AML aged 60&#x000a0;years or older were included in the present study. All patients were enrolled between May 1997 and February 1999 in an international, multigroup, randomized phase 3 trial performed under auspices of the Dutch&#x02013;Belgian Hemato-Oncology Cooperative Group and the UK Medical Research Council [<xref ref-type="bibr" rid="CR14">14</xref>]. In that trial, 419 eligible white patients &#x02265;60&#x000a0;years with previously untreated de novo and secondary AML (M0&#x02013;M2 and M4&#x02013;M7 according to the French&#x02013;American&#x02013;British [FAB] classification [<xref ref-type="bibr" rid="CR15">15</xref>]) were randomized to receive two cycles of induction chemotherapy consisting of daunorubicin (DNR) and cytarabine (ara-C) with or without the P-gp inhibitor PSC-833 (Valspodar, Amdray&#x000ae;; Novartis Pharma, Basle, Switzerland). Patients in both arms in complete remission after these two cycles were to receive one consolidation consisting of ara-C, MXT, and etoposide. Inclusion criteria, clinical characteristics, treatment, and outcome of the phase 3 trial have been previously reported [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Bone marrow (BM) aspirates had been collected at diagnosis for the analysis of P-gp function and expression, as described previously [<xref ref-type="bibr" rid="CR14">14</xref>]. Selection of patients for our study was based on availability of sufficient purified AML blast samples in our tissue bank, which was the case for 154 patients.</p><p>This study was approved by the ethics committees of the participating institutions and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients before randomization.</p></sec><sec id="Sec4"><title>Methods</title><p>BM aspirates were obtained in heparinized tubes. Mononuclear BM cells were collected by Ficoll Hypaque density gradient centrifugation (density 1.077&#x000a0;g/m<sup>3</sup>; Pharmacia, Uppsala, Sweden). To obtain purified samples with more than 85% of blasts, T-cell depletion and adherence depletion was performed as previously described [<xref ref-type="bibr" rid="CR16">16</xref>]. Cells were cryopreserved in Dulbecco modified Eagle medium (DMEM; Gibco, Paisley, UK) supplemented with 10% dimethyl sulfoxide (Merck, Darmstadt, Germany) and 20% fetal calf serum (FCS; Gibco) and stored in liquid nitrogen. On the day of the experiments, BM cells were thawed. Cells were washed and resuspended in DMEM supplemented with 10% FCS. Before RNA and DNA isolation, cells were washed with phosphate-buffered saline (Gibco).</p></sec><sec id="Sec5"><title>MDR1, MRP1, LRP, and BCRP mRNA analysis</title><p>The drug resistance proteins were analyzed using the methods that we previously reported [<xref ref-type="bibr" rid="CR11">11</xref>]. In brief, total RNA was isolated using the TRISOLV&#x02122; extraction as described by the manufacturer (Biotecx, Houston, TX). RNA was aliquoted and stored at &#x02212;80&#x000b0;C. RNA samples were analyzed for RNA integrity by gel electrophoresis. cDNA was synthesized by the use of the TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA), diluted, aliquoted, and stored at &#x02212;80&#x000b0;C. Quantitative RT-PCR was used to measure the mRNA expression levels of <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> by Taqman-chemistry on an ABI PRISM 7700 sequence detector (Applied Biosystems) using two endogenous reference genes, i.e., glyceraldehyde-3-phosphate dehydrogenase and porphobilinogen deaminase.</p></sec><sec id="Sec6"><title>Definition of endpoints</title><p>The clinical endpoints have been defined previously [<xref ref-type="bibr" rid="CR14">14</xref>]. In brief, complete response (CR) was defined as a normocellular BM with &#x0003c;5% blasts, no Auer rods, and no evidence of extramedullary involvement. Because data on peripheral blood recovery within 60&#x000a0;days were not always available, they were not considered as a criterium for CR. Patients who relapsed or died within 28&#x000a0;days after CR were considered as not having achieved a CR. Event-free survival (EFS) was calculated from the date of randomization until no CR on induction therapy, relapse after CR, or death in CR, whichever came first. Patients who did not reach CR were considered failure for EFS at 1&#x000a0;day after randomization. Disease-free survival (DFS) was determined for all patients who achieved CR on induction therapy and was calculated from the date of CR until relapse or death, whichever came first. Overall survival (OS) was measured from randomization until death from any cause. Patients who were still alive at the date of last contact were then censored.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>The original phase 3 trial had been designed to detect with a power of 80% an increase in 2-year EFS from 9.5% in the control arm (without PSC-833) to 18% in the PSC-833 arm (two-sided significance level <italic>&#x003b1;</italic>&#x02009;=&#x02009;0.05) and included 419 eligible patients.</p><p>mRNA data were obtained from a subset of 154 patients with sufficient BM samples in our tissue bank available for analysis. Baseline parameters of interest were <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> mRNA expression. Clinical endpoints were CR rate, EFS, DFS, and OS.</p><p>Baseline characteristics of patients with or without mRNA expression data available were compared using the Fisher exact test or the Pearson <italic>&#x003c7;</italic><sup>2</sup> test in case of discrete variables, whichever appropriate, or the Wilcoxon rank-sum test in case of continuous variables. The association between patient baseline characteristics and mRNA expression levels was analyzed using the Pearson <italic>&#x003c7;</italic><sup>2</sup> test of the Spearman rank correlation test, whichever was appropriate. The prognostic value of mRNA levels with respect to CR rate was determined using logistic regression [<xref ref-type="bibr" rid="CR17">17</xref>] whereas the impact of <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> on EFS, DFS, and OS was analyzed with Cox regression analysis [<xref ref-type="bibr" rid="CR18">18</xref>]. For this purpose, the natural logarithm of the mRNA expression levels of the four resistance genes were included in the analyses because of the very skewed distribution of the original mRNA levels. In addition, the outcome of patients with coexpression of <italic>MDR1</italic> and <italic>BCRP</italic> was evaluated to confirm the poor prognosis of AML with <italic>MDR1</italic>/<italic>BCRP</italic> coexpression reported by Benderra et al. [<xref ref-type="bibr" rid="CR19">19</xref>] in patients with a median age of 45&#x000a0;years or older. These patients were defined as having mRNA levels of these two drug resistance genes equal to or higher than the median. Their outcome was compared to the other patients with at least one of the <italic>MDR1</italic> and <italic>BCRP</italic> mRNA expression levels below the median. Logistic regression and Cox regression analyses were performed unadjusted, as well as adjusted for other prognostic factors, i.e., secondary AML, natural logarithm of WBC count, square root of percentage CD34<sup>+</sup> cells, and cytogenetic risk (favorable/intermediate versus unfavorable versus unknown), as well as for treatment arm in the phase 3 trial, as about half of the patients had been randomized to receive PSC-833 in addition to their chemotherapy. Kaplan&#x02013;Meier curves [<xref ref-type="bibr" rid="CR20">20</xref>] were generated to illustrate survival and were compared using the log-rank test [<xref ref-type="bibr" rid="CR21">21</xref>]. All reported <italic>p</italic> values are two-sided and, in view of the exploratory nature of these analyses, were calculated without adjustment for multiple testing. <italic>p</italic> values&#x02009;&#x02264;&#x02009;0.05 were considered statistically significant.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><p>In the phase 3 trial, a total of 419 untreated patients with AML aged 60&#x000a0;years and older were randomized to receive two induction cycles with or without PSC-833. As reported, no difference was found between both treatment arms as regards CR rate (54% in the PSC-833 arm versus 48% in the control arm, <italic>p</italic>&#x02009;=&#x02009;0.22), 5-year EFS (7 versus 8%, <italic>p</italic>&#x02009;=&#x02009;0.53) nor DFS (13 versus 17%, <italic>p</italic>&#x02009;=&#x02009;0.06) and OS (10% in both arms, <italic>p</italic>&#x02009;=&#x02009;0.52) [<xref ref-type="bibr" rid="CR14">14</xref>]. We previously reported the role of functional MDR1 expression with respect to clinical outcome in these patients.</p><p>In 154/419 of the patients, sufficient BM cells were available in our tissue bank to investigate the mRNA expression level of the drug resistance genes <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic>. This subgroup consisted of a representative group according to age, gender, CD34 expression, cytogenetics, and FAB classification (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). In this test group, a higher WBC count at diagnosis was observed than in the other 265 patients, and relatively more patients had been randomized to the PSC-833 arm (57 versus 45%, <italic>p</italic>&#x02009;=&#x02009;0.02). There was no significant difference in the levels of <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, nor <italic>BCRP</italic> mRNA expression between the two treatment arms (data not shown). The CR rate and survival endpoints were also similar in both patient groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). However, patients with mRNA data in the PSC-833 arm had a higher CR rate (61 versus 40%, <italic>p</italic>&#x02009;=&#x02009;0.02), whereas this was 54 versus 48% (<italic>p</italic>&#x02009;=&#x02009;0.22) in all 419 patients. <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Comparison between patients with or without data available for expression of the drug resistance genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#x000a0;</th><th colspan="2">Drug resistance genes evaluated</th><th colspan="2">&#x000a0;</th></tr><tr><th>Yes <italic>N</italic> (%)</th><th>No <italic>N</italic> (%)</th><th>Total <italic>N</italic> (%)</th><th><italic>p</italic></th></tr></thead><tbody><tr><td>Number of patients</td><td align="left">154</td><td align="left">265</td><td align="left">419</td><td/></tr><tr><td colspan="5">Patient characteristics</td></tr><tr><td>Median age, (range)</td><td>67 (60&#x02013;85)</td><td>68 (58&#x02013;85)</td><td>67 (58&#x02013;85)</td><td align="left">0.52</td></tr><tr><td>Sex</td><td/><td/><td/><td align="left">0.26</td></tr><tr><td>&#x000a0;Male</td><td>86 (56)</td><td>163 (62)</td><td>249 (59)</td><td/></tr><tr><td>&#x000a0;Female</td><td>68 (44)</td><td>102 (38)</td><td>170 (41)</td><td/></tr><tr><td>Secondary AML</td><td>31 (20)</td><td>73 (28)</td><td>104 (25)</td><td align="left">0.09</td></tr><tr><td>Median WBC count (&#x000d7;10<sup>9</sup>/l; range)</td><td>19.1 (0.1&#x02013;389)</td><td>5.6 (0.5&#x02013;300)</td><td>8.9 (0.1&#x02013;389)</td><td align="left">0.001</td></tr><tr><td><italic>N</italic></td><td align="left">146</td><td align="left">243</td><td align="left">389</td><td/></tr><tr><td>Median % CD34<sup>+</sup>, (range)</td><td>32.5 (0.1&#x02013;97.9)</td><td>29.7 (0.1&#x02013;93.7)</td><td>30.3 (0.1&#x02013;97.9)</td><td align="left">0.50</td></tr><tr><td><italic>N</italic></td><td align="left">152</td><td align="left">157</td><td align="left">309</td><td/></tr><tr><td>Cytogenetic risk classification<sup>a</sup></td><td/><td/><td/><td align="left">0.12</td></tr><tr><td>&#x000a0;Favorable</td><td>3 (3)</td><td>2 (1)</td><td>5 (2)</td><td/></tr><tr><td>&#x000a0;Intermediate</td><td>90 (80)</td><td>132 (73)</td><td>222 (76)</td><td/></tr><tr><td>&#x000a0;Unfavorable</td><td>19 (17)</td><td>47 (26)</td><td>66 (23)</td><td/></tr><tr><td>&#x000a0;No data</td><td>42 (n.i.)</td><td>84 (n.i.)</td><td>126 (n.i.)</td><td/></tr><tr><td>Treatment arm randomized</td><td/><td/><td/><td align="left">0.02</td></tr><tr><td>&#x000a0;DNR/ara-C</td><td>66 (43)</td><td>145 (55)</td><td>211 (50)</td><td/></tr><tr><td>&#x000a0;DNR/ara-C +PSC-833</td><td>88 (57)</td><td>120 (45)</td><td>208 (50)</td><td/></tr><tr><td colspan="5">Treatment outcome</td></tr><tr><td>CR rate, % (95% CI)</td><td>52 (44&#x02013;60)</td><td>50 (44&#x02013;56)</td><td>51 (46&#x02013;56)</td><td align="left">0.73</td></tr><tr><td>EFS, % (95% CI)</td><td/><td/><td/><td align="left">0.72</td></tr><tr><td>&#x000a0;1&#x000a0;year</td><td>23 (17&#x02013;30)</td><td>23 (18&#x02013;28)</td><td>23 (19&#x02013;27)</td><td/></tr><tr><td>&#x000a0;5&#x000a0;years</td><td>9 (5&#x02013;14)</td><td>7 (4&#x02013;11)</td><td>8 (5&#x02013;11)</td><td/></tr><tr><td>DFS, % (95% CI)</td><td/><td/><td/><td align="left">0.81</td></tr><tr><td>&#x000a0;1&#x000a0;year</td><td>38 (27&#x02013;48)</td><td>39 (31&#x02013;48)</td><td>39 (32&#x02013;45)</td><td/></tr><tr><td>&#x000a0;5&#x000a0;years</td><td>17 (10&#x02013;26)</td><td>14 (9&#x02013;21)</td><td>15 (11&#x02013;21)</td><td/></tr><tr><td>OS, % (95% CI)</td><td/><td/><td/><td align="left">0.31</td></tr><tr><td>&#x000a0;1&#x000a0;year</td><td>42 (34&#x02013;50)</td><td>41 (35&#x02013;46)</td><td>41 (36&#x02013;46)</td><td/></tr><tr><td>&#x000a0;5&#x000a0;years</td><td>14 (9&#x02013;20)</td><td>8 (5&#x02013;12)</td><td>10 (7&#x02013;14)</td><td/></tr></tbody></table><table-wrap-foot><p>The results indicate that, apart from WBC count, there are no differences between the two subgroups.</p><p><italic>N</italic> number of patients with data (if not available for all patients); <italic>n.i.</italic> not included when calculating percentages</p><p><sup>a</sup>Classification of cytogenetic abnormalities only for 293 patients with successful cytogenetics. Favorable risk: t(8;21), inv(16) or t(16;16). Unfavorable risk: the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q26), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone). Patients who did not meet the criteria for favorable or unfavorable risk were classified as intermediate risk [<xref ref-type="bibr" rid="CR14">14</xref>].</p></table-wrap-foot></table-wrap></p><p>The mRNA expression levels of the resistance genes were not significantly associated with the age of the patients (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). <italic>MRP1</italic> and <italic>LRP</italic> expression showed a strong positive correlation with WBC count. Negative associations of <italic>MDR1</italic> and <italic>BCRP</italic> with WBC count were observed. A significant positive association was found between CD34 and <italic>MDR1</italic> and also with <italic>BCRP</italic> mRNA expression. No significant correlation was found between <italic>MRP1</italic> nor <italic>LRP</italic>, and CD34 expression (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Interestingly, secondary AML cases had a significantly higher expression of <italic>BCRP</italic> (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) and lower <italic>MRP1</italic> and <italic>LRP</italic> levels (both <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In the vast majority of our patients, also P-gp efflux and expression data were available. Function and expression data and <italic>MDR1</italic> mRNA expression levels were highly correlated (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), which was published recently [<xref ref-type="bibr" rid="CR22">22</xref>]. <table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Association between clinical patient characteristics and the mRNA expression of the four drug resistance genes and <italic>MDR1</italic>/<italic>BCRP</italic> coexpression</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#x000a0;</th><th colspan="5">mRNA expression of</th></tr><tr><th><italic>MDR1</italic></th><th><italic>MRP1</italic></th><th><italic>LRP</italic></th><th><italic>BCRP</italic></th><th><italic>MDR1</italic>/<italic>BCRP</italic> coexpression</th></tr></thead><tbody><tr><td colspan="6">Characteristic</td></tr><tr><td rowspan="2">&#x000a0;Age</td><td>0.15</td><td>&#x02212;0.01</td><td>&#x02212;0.09</td><td>0.09</td><td>0.07</td></tr><tr><td>(153)</td><td>(153)</td><td>(153)</td><td>(137)</td><td>(147)</td></tr><tr><td rowspan="2">&#x000a0;Secondary AML</td><td>0.06</td><td>&#x02212;0.22**</td><td>&#x02212;0.21**</td><td>0.19*</td><td>0.12</td></tr><tr><td>(153)</td><td>(153)</td><td>(153)</td><td>(137)</td><td>(147)</td></tr><tr><td rowspan="2">&#x000a0;WBC count</td><td>&#x02212;0.17*</td><td>0.28***</td><td>0.36***</td><td>&#x02212;0.36***</td><td>&#x02212;0.35***</td></tr><tr><td>(145)</td><td>(145)</td><td>(145)</td><td>(131)</td><td>(139)</td></tr><tr><td rowspan="2">&#x000a0;CD34<sup>+</sup></td><td>0.54***</td><td>0.14</td><td>&#x02212;0.08</td><td>0.17*</td><td>0.27**</td></tr><tr><td>(151)</td><td>(151)</td><td>(151)</td><td>(135)</td><td>(145)</td></tr><tr><td>&#x000a0;Unfavorable </td><td>0.11</td><td>&#x02212;0.05</td><td>&#x02212;0.23*</td><td>0.13</td><td>0.10</td></tr><tr><td>&#x000a0;Cytogenetic risk</td><td>(111)</td><td>(111)</td><td>(111)</td><td>(98)</td><td>(106)</td></tr></tbody></table><table-wrap-foot><p>Unfavorable cytogenetic risk was defined by the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q6), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23), or complex cytogenetic abnormalities (defined as at least three unrelated cytogenetic abnormalities in one clone)</p><p>Each cell displays the Spearman rank correlation coefficient between two variables and, between brackets, the number of patients with both variables available.</p><p>*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01; ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001</p></table-wrap-foot></table-wrap></p><p>In this cohort of patients of higher age with AML, <italic>MDR1</italic> and <italic>BCRP</italic> were highly associated (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), just as were <italic>MRP1</italic> and <italic>LRP</italic> mRNA (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). A negative association was found between <italic>BCRP</italic> and <italic>MRP1</italic> and between <italic>BCRP</italic> and <italic>LRP</italic> (both <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The 40 patients with coexpression of <italic>BCRP</italic> and <italic>MDR1</italic> had significantly higher CD34 expression (median 39.5% [range 0.1&#x02013;97.7%] versus 25.9% [range 0.1&#x02013;97.9%]; <italic>p</italic>&#x02009;=&#x02009;0.001) and a lower WBC count (median 4.5 [range 0.8&#x02013;300]&#x000d7;10<sup>9</sup>/l versus 28.1 [range 0.1&#x02013;389]&#x000d7;10<sup>9</sup>/l; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). No significant correlation of <italic>MDR1</italic>, <italic>BCRP</italic>, or coexpression of <italic>MDR1</italic> and <italic>BCRP</italic> was found with unfavorable cytogenetics (<italic>p</italic>&#x02009;=&#x02009;0.4; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). <fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Association between <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> mRNA expression levels. Each <italic>dot</italic> represents the expression of two drug resistance genes in one patient. The Spearman rank correlation coefficient has been calculated, along with the corresponding <italic>p</italic> value. Both the <italic>x</italic>- and <italic>y</italic>-axis have a logarithmic scale trim(<italic>X</italic>)* indicates that the 2.5% smallest and largest values of <italic>X</italic> have been shrinked; <italic>r</italic>, Spearman rank correlation coefficient; and <italic>p</italic>, <italic>p</italic> value. The results show a significant positive correlation between <italic>MDR1</italic> and <italic>BCRP</italic> mRNA expression as illustrated by the <italic>p</italic> value and correlation coefficient. In addition, <italic>MRP1</italic> and <italic>LRP</italic> are highly associated. <italic>BCRP</italic> shows a negative correlation with <italic>MRP1</italic> and <italic>LRP</italic></p></caption><graphic position="anchor" xlink:href="277_2007_269_Fig1_HTML" id="MO1"/></fig></p><p>To assess the clinical relevance of the four resistance genes, their expression was evaluated with regard to CR rate and survival data, respectively. The median follow-up of the 25 patients still alive was 58&#x000a0;months (range, 1&#x02013;80&#x000a0;months). Univariate logistic regression analysis showed that higher <italic>MDR1</italic> mRNA expression predicted for a lower CR rate (log[<italic>MDR1</italic>]: odds ratio [OR]=0.75, 95% confidence interval [CI] 0.61&#x02013;0.93, <italic>p</italic>&#x02009;=&#x02009;0.009), whereas <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> mRNA were not associated with CR (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). <italic>MDR1</italic> expression was also associated with a worse EFS (log[<italic>MDR1</italic>]: hazard ratio [HR]=1.14, 95% CI 1.03&#x02013;1.27, <italic>p</italic>&#x02009;=&#x02009;0.01) and OS (log[<italic>MDR1</italic>]: HR&#x02009;=&#x02009;1.16, 95% CI 1.05&#x02013;1.29, <italic>p</italic>&#x02009;=&#x02009;0.004). Similar results were also obtained for <italic>MDR1</italic>/<italic>BCRP</italic> coexpression (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). When the analyses were performed with adjustment for other prognostic factors, as described in the &#x0201c;<xref rid="Sec7" ref-type="sec">Statistical analysis</xref>&#x0201d;, only <italic>MDR1</italic>/<italic>BCRP</italic> mRNA coexpression remained significantly associated with a lower CR rate (OR&#x02009;=&#x02009;0.37, 95% CI 0.15&#x02013;0.91, <italic>p</italic>&#x02009;=&#x02009;0.03), whereas a trend was observed for worse EFS (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). On the other hand, higher CD34 expression was significantly associated with a lower CR rate (square root[CD34]: OR&#x02009;=&#x02009;0.86, 95% CI 0.76&#x02013;0.98, <italic>p</italic>&#x02009;=&#x02009;0.02) and with worse EFS (HR&#x02009;=&#x02009;1.12, 95% CI 1.06&#x02013;1.19, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), DFS (HR&#x02009;=&#x02009;1.19, 95% CI 1.09&#x02013;1.30, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), and OS (HR&#x02009;=&#x02009;1.17, 95% CI&#x02009;=&#x02009;1.10&#x02013;1.25, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). <table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Prognostic value of drug resistance gene expression w.r.t. CR rate, EFS, DFS from CR, and OS</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#x000a0;</th><th colspan="3">CR rate</th><th colspan="3">EFS</th><th colspan="3">DFS</th><th colspan="3">OS</th></tr><tr><th>OR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th><th>HR</th><th>95% CI</th><th><italic>p</italic></th></tr></thead><tbody><tr><td><italic>MDR1</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Univariate</td><td align="center">0.75</td><td>0.61&#x02013;0.93</td><td align="center">0.009</td><td align="center">1.14</td><td>1.03&#x02013;1.27</td><td align="center">0.01</td><td align="center">1.13</td><td>0.97&#x02013;1.30</td><td align="center">0.11</td><td align="center">1.16</td><td>1.05&#x02013;1.29</td><td align="center">0.004</td></tr><tr><td>&#x000a0;Adjusted</td><td align="center">0.77</td><td>0.58&#x02013;1.03</td><td align="center">0.08</td><td align="center">1.05</td><td>0.91&#x02013;1.21</td><td align="center">0.48</td><td align="center">0.95</td><td>0.77&#x02013;1.18</td><td align="center">0.67</td><td align="center">1.00</td><td>0.87&#x02013;1.16</td><td align="center">0.97</td></tr><tr><td><italic>MRP1</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Univariate</td><td align="center">1.06</td><td>0.83&#x02013;1.35</td><td align="center">0.63</td><td align="center">1.02</td><td>0.90&#x02013;1.15</td><td align="center">0.79</td><td align="center">1.07</td><td>0.89&#x02013;1.29</td><td align="center">0.47</td><td align="center">1.11</td><td>0.97&#x02013;1.26</td><td align="center">0.12</td></tr><tr><td>&#x000a0;Adjusted</td><td align="center">1.22</td><td>0.90&#x02013;1.66</td><td align="center">0.20</td><td align="center">1.00</td><td>0.87&#x02013;1.15</td><td align="center">0.98</td><td align="center">1.12</td><td>0.92&#x02013;1.37</td><td align="center">0.26</td><td align="center">1.05</td><td>0.91&#x02013;1.21</td><td align="center">0.54</td></tr><tr><td><italic>LRP</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Univariate</td><td align="center">1.16</td><td>0.94&#x02013;1.43</td><td align="center">0.16</td><td align="center">0.95</td><td>0.86&#x02013;1.06</td><td align="center">0.36</td><td align="center">0.98</td><td>0.84&#x02013;1.14</td><td align="center">0.79</td><td align="center">0.97</td><td>0.87&#x02013;1.08</td><td align="center">0.60</td></tr><tr><td>&#x000a0;Adjusted</td><td align="center">1.22</td><td>0.93&#x02013;1.61</td><td align="center">0.15</td><td align="center">0.99</td><td>0.87&#x02013;1.12</td><td align="center">0.83</td><td align="center">1.06</td><td>0.89&#x02013;1.27</td><td align="center">0.52</td><td align="center">0.98</td><td>0.86&#x02013;1.12</td><td align="center">0.78</td></tr><tr><td><italic>BCRP</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Univariate</td><td align="center">0.84</td><td>0.66&#x02013;1.06</td><td align="center">0.14</td><td align="center">1.04</td><td>0.91&#x02013;1.18</td><td align="center">0.58</td><td align="center">0.95</td><td>0.77&#x02013;1.16</td><td align="center">0.60</td><td align="center">0.96</td><td>0.84&#x02013;1.10</td><td align="center">0.58</td></tr><tr><td>&#x000a0;Adjusted</td><td align="center">0.79</td><td>0.59&#x02013;1.06 </td><td align="center">0.12</td><td align="center">0.99</td><td>0.86&#x02013;1.14</td><td align="center">0.92</td><td align="center">0.84</td><td>0.66&#x02013;1.06</td><td align="center">0.14</td><td align="center">0.90</td><td>0.77&#x02013;1.05</td><td align="center">0.19</td></tr><tr><td><italic>MDR1</italic>/<italic>BCRP</italic> co-expression</td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Univariate</td><td align="center">0.38</td><td>0.18&#x02013;0.80</td><td align="center">0.01</td><td align="center">1.63</td><td>1.11&#x02013;2.37</td><td align="center">0.01</td><td align="center">1.65</td><td>0.90&#x02013;3.01</td><td align="center">0.11</td><td align="center">1.47</td><td>1.00&#x02013;2.16</td><td align="center">0.05</td></tr><tr><td>&#x000a0;Adjusted</td><td align="center">0.37</td><td>0.15&#x02013;0.92 </td><td align="center">0.03</td><td align="center">1.53</td><td>0.98&#x02013;2.38</td><td align="center">0.06</td><td align="center">1.37</td><td>0.67&#x02013;2.82</td><td align="center">0.39</td><td align="center">1.16</td><td>0.74&#x02013;1.83</td><td align="center">0.51</td></tr></tbody></table><table-wrap-foot><p>Results of logistic (for CR rate) and Cox regression (for survival) analyses, either univariate (=unadjusted) or adjusted for treatment arm, secondary AML, WBC count (natural logarithm), % CD34<sup>+</sup> (square root), and cytogenetic risk (favorable/intermediate versus unfavorable versus unknown), are shown for each of the four drug resistance genes <italic>MDR1</italic>, <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> (natural logarithm of mRNA expression levels) and for <italic>MDR1</italic>/<italic>BCRP</italic> co-expression.</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Survival of elderly AML patients with and without coexpression of <italic>MDR1</italic> and <italic>BCRP mRNA</italic>. <bold>a</bold> Event-free survival, <bold>b</bold> disease-free survival, <bold>c</bold> overall survival. <italic>pos</italic> indicates patients with coexpression of <italic>MDR1</italic> and <italic>BCRP</italic>; and <italic>other</italic>, patients without coexpression</p></caption><graphic position="anchor" xlink:href="277_2007_269_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec9" sec-type="discussion"><title>Discussion</title><p>This is the first comprehensive analysis of the effect of the major classical MDR genes in a cohort of elderly patients with AML homogeneously treated in a prospective clinical trial [<xref ref-type="bibr" rid="CR14">14</xref>]. A wide range of expression of the various resistance genes was observed, consistent with previous studies and with comparable median values [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Our results show that <italic>MRP1</italic>, <italic>LRP</italic>, and <italic>BCRP</italic> are not associated with CR rate or survival endpoints in patients with AML aged 60&#x000a0;years or older, indicating that the clinical relevance of the expression of these genes is limited in this patient population. This study confirms previous reports, which showed the unique prognostic role of MDR1 expression&#x02014;which was however highly correlated with CD34 expression&#x02014;in drug resistance in elderly AML (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), in contrast to the prognostic value of MRP1 expression in AML, which has shown conflicting results, whereas currently, LRP is no longer thought to be important for clinical drug resistance [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Recently, two studies in, respectively, 40 and 31 adult AML patients showed no effect of <italic>BCRP</italic> gene expression on CR rate, whereas OS was lower in patients with the highest <italic>BCRP</italic> expression [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Damiani et al. [<xref ref-type="bibr" rid="CR28">28</xref>] showed that <italic>BCRP</italic> expression did not influence achievement of complete remission in AML patients with a median age of 53&#x000a0;years and normal karyotype, however, <italic>BCRP</italic> expression was associated with higher relapse rate. In 59 children with de novo AML, a higher <italic>BCRP</italic> expression was observed in patients who did not reach CR, but this was not translated in poorer survival [<xref ref-type="bibr" rid="CR29">29</xref>]. Benderra et al. [<xref ref-type="bibr" rid="CR19">19</xref>] indicated that <italic>BCRP</italic> gene expression was an adverse prognostic factor for CR in a group of 149 relatively younger adult AML patients but only in patients treated with DNR and MXT and not with idarubicin. In our cohort of elderly AML patients who were all treated with DNR, whereas MXT was given as consolidation therapy after reaching CR, a significant correlation of <italic>BCRP</italic> mRNA expression with lower CR rate could not be shown.</p><p>Our study confirms that <italic>BCRP</italic> and <italic>MDR1</italic> are coexpressed in AML patients with higher age as has been suggested previously from studies in smaller groups of relatively younger AML patients [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Until now, only two studies have evaluated the clinical value of coexpression of <italic>MDR1</italic> and <italic>BCRP</italic> in a sufficient number, although relatively younger adult AML patients [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Benderra et al. [<xref ref-type="bibr" rid="CR19">19</xref>] showed that CR rate was only 45% in the patients with coexpression of <italic>BCRP</italic> and <italic>MDR1</italic> (+/+) in comparison with 66% in the <italic>MDR1</italic>/<italic>BCRP</italic>&#x02212;/+ and +/&#x02212;group and 90% in the <italic>MDR1/BCRP</italic>&#x02212;/&#x02212;group (<italic>p</italic>&#x02009;=&#x02009;0.003). Moreover, a significantly lower DFS and OS were found in the <italic>MDR1</italic>/<italic>BCRP</italic>+/+group. Damiani et al. [<xref ref-type="bibr" rid="CR28">28</xref>] found a trend towards a higher relapse rate in the small group of <italic>BCRP</italic>+/<italic>MDR1</italic>+patients, indicating that this represents a robust resistant AML phenotype, consistent with our findings in elderly AML. The recent finding that <italic>BCRP</italic> and <italic>MDR1</italic> expression was mainly found in the most resistant group of AML, using gene expression profiling, underscores the role of these drug resistance genes in AML [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p>However, this study shows, that the prominent prognostic role of CD34 expression in elderly AML should be emphasized, as higher CD34 expression was adversely associated with all clinical endpoints. <italic>MDR1</italic> and <italic>BCRP</italic> but not <italic>MRP1</italic> and <italic>LRP</italic> mRNA expression were found to be associated with high CD34 expression in these elderly AML patients, which may explain why <italic>MDR1</italic> was no longer significant for CR rate, EFS, and OS when adjusted for other prognostic variables including CD34. In the past, MDR1 expression has been linked to the CD34-positive hematopoietic stem cell compartment of the leukemia subtype. In two other studies in younger AML patients, no overexpression (on mRNA and protein level) of <italic>BCRP</italic> in the CD34-positive blast population of clinical AML samples was found [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. In contrast, earlier studies in mice demonstrated high levels of <italic>BCRP</italic> and <italic>MDR1</italic> expression in normal hematopoietic stem cells [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>]. Previously, <italic>BCRP</italic> expression in subsets of stem cells has been reported, indicating that high <italic>BCRP</italic> expression may exist in CD34<sup>+</sup>/CD38<sup>&#x02212;</sup> cells or in CD34<sup>+</sup>/CD33<sup>&#x02212;</sup>cells [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. The differential expression of <italic>BCRP</italic> and <italic>MDR1</italic> in specific subsets of hematopoietic stem cells is consistent with the side population phenotype as proposed by Goodell et al. [<xref ref-type="bibr" rid="CR36">36</xref>] who claim that BCRP expression can be separated from those expressing the other ABC proteins. This would suggest that BCRP is expressed in even less differentiated hematopoietic stem cells than MDR1 [<xref ref-type="bibr" rid="CR19">19</xref>]. In our study in AML, these immature subsets could not be separately investigated, however, the unique <italic>BCRP/MDR1</italic>+/+subgroup of patients reflects an immature leukemic cell type that has a very resistant phenotype in vivo, illustrated by a low CR rate and poor outcome (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p>This is the first study in which a correlation was found between secondary AML and a high expression of <italic>BCRP</italic> mRNA but not the other resistance proteins. In addition to our previous report that <italic>BCRP</italic> is frequently upregulated in patients with AML at relapse, we now demonstrate that expression of <italic>BCRP</italic> is representative of secondary AML, which is especially observed in elderly patients [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Recently, Ross [<xref ref-type="bibr" rid="CR37">37</xref>] suggested that MDR modifiers may be of benefit for patients with multiple dysplastic features. This may suggest that <italic>BCRP</italic> is upregulated in diseases in which exposure to xenobiotics during life plays an etiologic role.</p><p>We conclude that coexpression of CD34-related coexpression of <italic>MDR1</italic> and <italic>BCRP</italic> reflects a clinically resistant subgroup of elderly AML. In this age group, only <italic>BCRP</italic> is correlated with secondary AML. As such, the development of new treatment strategies for elderly AML patients may focus on modulation of drug resistance targeting both <italic>BCRP</italic> and <italic>MDR1</italic>.</p></sec></body><back><ack><title>Acknowledgements</title><p>We acknowledge M. Schoester and A. Prins for their technical assistance and Dr. P.P. Piccaluga and Dr. P.J.M. Vossebeld for their contribution to this study.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunault</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Delmer</surname><given-names>A</given-names></name><name><surname>Ramond</surname><given-names>S</given-names></name><name><surname>Viguie</surname><given-names>F</given-names></name><name><surname>Cadiou</surname><given-names>M</given-names></name><etal/></person-group><article-title>Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment</article-title><source>Ann Hematol</source><year>1997</year><volume>74</volume><issue>2</issue><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s002770050259</pub-id></citation><citation citation-type="display-unstructured">Hunault M, Zhou D, Delmer A, Ramond S, Viguie F, Cadiou M et al (1997) Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann Hematol 74(2):65&#x02013;71 <pub-id pub-id-type="pmid">9063375</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leith</surname><given-names>CP</given-names></name><name><surname>Kopecky</surname><given-names>KJ</given-names></name><name><surname>Chen</surname><given-names>IM</given-names></name><name><surname>Eijdems</surname><given-names>L</given-names></name><name><surname>Slovak</surname><given-names>ML</given-names></name><name><surname>McConnell</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study</article-title><source>Blood</source><year>1999</year><volume>94</volume><issue>3</issue><fpage>1086</fpage><lpage>1099</lpage></citation><citation citation-type="display-unstructured">Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS et al (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94(3):1086&#x02013;1099 <pub-id pub-id-type="pmid">10419902</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heuvel-Eibrink</surname><given-names>MM</given-names></name><name><surname>Holt</surname><given-names>B</given-names></name><name><surname>Boekhorst</surname><given-names>PA</given-names></name><name><surname>Pieters</surname><given-names>R</given-names></name><name><surname>Schoester</surname><given-names>M</given-names></name><name><surname>Lowenberg</surname><given-names>B</given-names></name><etal/></person-group><article-title>MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia</article-title><source>Br J Haematol</source><year>1997</year><volume>99</volume><issue>1</issue><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2141.1997.3343148.x</pub-id></citation><citation citation-type="display-unstructured">van den Heuvel-Eibrink MM, van der Holt B, te Boekhorst PA, Pieters R, Schoester M, Lowenberg B et al (1997) MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol 99(1):76&#x02013;83 <pub-id pub-id-type="pmid">9359506</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willman</surname><given-names>CL</given-names></name></person-group><article-title>The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program</article-title><source>Semin Hematol</source><year>1997</year><volume>34</volume><issue>4 Suppl 5</issue><fpage>25</fpage><lpage>33</lpage></citation><citation citation-type="display-unstructured">Willman CL (1997) The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 34(4 Suppl 5):25&#x02013;33 <pub-id pub-id-type="pmid">9408958</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mossink</surname><given-names>MH</given-names></name><name><surname>Zon</surname><given-names>A</given-names></name><name><surname>Scheper</surname><given-names>RJ</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Wiemer</surname><given-names>EA</given-names></name></person-group><article-title>Vaults: a ribonucleoprotein particle involved in drug resistance</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><issue>47</issue><fpage>7458</fpage><lpage>7467</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206947</pub-id></citation><citation citation-type="display-unstructured">Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA (2003) Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 22(47):7458&#x02013;7467 <pub-id pub-id-type="pmid">14576851</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kolk</surname><given-names>DM</given-names></name><name><surname>Vries</surname><given-names>EG</given-names></name><name><surname>Noordhoek</surname><given-names>L</given-names></name><name><surname>Berg</surname><given-names>E</given-names></name><name><surname>Pol</surname><given-names>MA</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><etal/></person-group><article-title>Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia</article-title><source>Leukemia</source><year>2001</year><volume>15</volume><issue>10</issue><fpage>1544</fpage><lpage>1553</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2402236</pub-id></citation><citation citation-type="display-unstructured">van der Kolk DM, de Vries EG, Noordhoek L, van den Berg E, van der Pol MA, Muller M et al (2001) Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 15(10):1544&#x02013;1553 <pub-id pub-id-type="pmid">11587212</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zon</surname><given-names>A</given-names></name><name><surname>Mossink</surname><given-names>MH</given-names></name><name><surname>Schoester</surname><given-names>M</given-names></name><name><surname>Scheper</surname><given-names>RJ</given-names></name><name><surname>Sonneveld</surname><given-names>P</given-names></name><name><surname>Wiemer</surname><given-names>EA</given-names></name></person-group><article-title>Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><issue>14</issue><fpage>4887</fpage><lpage>4892</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3891</pub-id></citation><citation citation-type="display-unstructured">van Zon A, Mossink MH, Schoester M, Scheper RJ, Sonneveld P, Wiemer EA (2004) Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression. Cancer Res 64(14):4887&#x02013;4892 <pub-id pub-id-type="pmid">15256459</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>LA</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Abruzzo</surname><given-names>LV</given-names></name><name><surname>Krogmann</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Rishi</surname><given-names>AK</given-names></name><etal/></person-group><article-title>A multidrug resistance transporter from human MCF-7 breast cancer cells</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><issue>26</issue><fpage>15665</fpage><lpage>15670</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.26.15665</pub-id></citation><citation citation-type="display-unstructured">Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK et al (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95(26):15665&#x02013;15670 <pub-id pub-id-type="pmid">9861027</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>DD</given-names></name><name><surname>Karp</surname><given-names>JE</given-names></name><name><surname>Chen</surname><given-names>TT</given-names></name><name><surname>Doyle</surname><given-names>LA</given-names></name></person-group><article-title>Expression of breast cancer resistance protein in blast cells from patients with acute leukemia</article-title><source>Blood</source><year>2000</year><volume>96</volume><issue>1</issue><fpage>365</fpage><lpage>368</lpage></citation><citation citation-type="display-unstructured">Ross DD, Karp JE, Chen TT, Doyle LA (2000) Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96(1):365&#x02013;368 <pub-id pub-id-type="pmid">10891476</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uggla</surname><given-names>B</given-names></name><name><surname>Stahl</surname><given-names>E</given-names></name><name><surname>Wagsater</surname><given-names>D</given-names></name><name><surname>Paul</surname><given-names>C</given-names></name><name><surname>Karlsson</surname><given-names>MG</given-names></name><name><surname>Sirsjo</surname><given-names>A</given-names></name><etal/></person-group><article-title>BCRP mRNA expression v. clinical outcome in 40 adult AML patients</article-title><source>Leuk Res</source><year>2005</year><volume>29</volume><issue>2</issue><fpage>141</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2004.06.004</pub-id></citation><citation citation-type="display-unstructured">Uggla B, Stahl E, Wagsater D, Paul C, Karlsson MG, Sirsjo A et al (2005) BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res 29(2):141&#x02013;146 <pub-id pub-id-type="pmid">15607361</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heuvel-Eibrink</surname><given-names>MM</given-names></name><name><surname>Wiemer</surname><given-names>EA</given-names></name><name><surname>Prins</surname><given-names>A</given-names></name><name><surname>Meijerink</surname><given-names>JP</given-names></name><name><surname>Vossebeld</surname><given-names>PJ</given-names></name><name><surname>Holt</surname><given-names>B</given-names></name><etal/></person-group><article-title>Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)</article-title><source>Leukemia</source><year>2002</year><volume>16</volume><issue>5</issue><fpage>833</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2402496</pub-id></citation><citation citation-type="display-unstructured">van den Heuvel-Eibrink MM, Wiemer EA, Prins A, Meijerink JP, Vossebeld PJ, van der Holt B et al (2002) Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 16(5):833&#x02013;839 <pub-id pub-id-type="pmid">11986944</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kolk</surname><given-names>DM</given-names></name><name><surname>Vellenga</surname><given-names>E</given-names></name><name><surname>Scheffer</surname><given-names>GL</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>Bates</surname><given-names>SE</given-names></name><name><surname>Scheper</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia</article-title><source>Blood</source><year>2002</year><volume>99</volume><issue>10</issue><fpage>3763</fpage><lpage>3770</lpage><pub-id pub-id-type="doi">10.1182/blood.V99.10.3763</pub-id></citation><citation citation-type="display-unstructured">van der Kolk DM, Vellenga E, Scheffer GL, Muller M, Bates SE, Scheper RJ et al (2002) Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99(10):3763&#x02013;3770 <pub-id pub-id-type="pmid">11986234</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pol</surname><given-names>MA</given-names></name><name><surname>Broxterman</surname><given-names>HJ</given-names></name><name><surname>Pater</surname><given-names>JM</given-names></name><name><surname>Feller</surname><given-names>N</given-names></name><name><surname>Maas</surname><given-names>M</given-names></name><name><surname>Weijers</surname><given-names>GW</given-names></name><etal/></person-group><article-title>Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia</article-title><source>Haematologica</source><year>2003</year><volume>88</volume><issue>2</issue><fpage>134</fpage><lpage>147</lpage></citation><citation citation-type="display-unstructured">van der Pol MA, Broxterman HJ, Pater JM, Feller N, van der Maas M, Weijers GW et al (2003) Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 88(2):134&#x02013;147 <pub-id pub-id-type="pmid">12604403</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>B</given-names></name><name><surname>Lowenberg</surname><given-names>B</given-names></name><name><surname>Burnett</surname><given-names>AK</given-names></name><name><surname>Knauf</surname><given-names>WU</given-names></name><name><surname>Shepherd</surname><given-names>J</given-names></name><name><surname>Piccaluga</surname><given-names>PP</given-names></name><etal/></person-group><article-title>The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis</article-title><source>Blood</source><year>2005</year><volume>106</volume><issue>8</issue><fpage>2646</fpage><lpage>2654</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-04-1395</pub-id></citation><citation citation-type="display-unstructured">van der Holt B, Lowenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP et al (2005) The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106(8):2646&#x02013;2654 <pub-id pub-id-type="pmid">15994288</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheson</surname><given-names>BD</given-names></name><name><surname>Cassileth</surname><given-names>PA</given-names></name><name><surname>Head</surname><given-names>DR</given-names></name><name><surname>Schiffer</surname><given-names>CA</given-names></name><name><surname>Bennett</surname><given-names>JM</given-names></name><name><surname>Bloomfield</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia</article-title><source>J Clin Oncol</source><year>1990</year><volume>8</volume><issue>5</issue><fpage>813</fpage><lpage>819</lpage></citation><citation citation-type="display-unstructured">Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD et al (1990) Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8(5):813&#x02013;819 <pub-id pub-id-type="pmid">2185339</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lowenberg</surname><given-names>B</given-names></name><name><surname>Putten</surname><given-names>WL</given-names></name><name><surname>Touw</surname><given-names>IP</given-names></name><name><surname>Delwel</surname><given-names>R</given-names></name><name><surname>Santini</surname><given-names>V</given-names></name></person-group><article-title>Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia</article-title><source>N Engl J Med</source><year>1993</year><volume>328</volume><issue>9</issue><fpage>614</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1056/NEJM199303043280904</pub-id></citation><citation citation-type="display-unstructured">Lowenberg B, van Putten WL, Touw IP, Delwel R, Santini V (1993) Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 328(9):614&#x02013;619 <pub-id pub-id-type="pmid">8429853</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hosmer</surname><given-names>DW</given-names></name><name><surname>Lemeshow</surname><given-names>S</given-names></name></person-group><source>Applied logistic regression</source><year>1989</year><publisher-loc>New York, NY</publisher-loc><publisher-name>Wiley</publisher-name></citation><citation citation-type="display-unstructured">Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York, NY </citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>DR</given-names></name></person-group><article-title>Regression models and life tables</article-title><source>J R Stat Soc</source><year>1972</year><volume>34</volume><fpage>187</fpage><lpage>220</lpage></citation><citation citation-type="display-unstructured">Cox DR (1972) Regression models and life tables. J R Stat Soc 34:187&#x02013;220 </citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benderra</surname><given-names>Z</given-names></name><name><surname>Faussat</surname><given-names>AM</given-names></name><name><surname>Sayada</surname><given-names>L</given-names></name><name><surname>Perrot</surname><given-names>JY</given-names></name><name><surname>Chaoui</surname><given-names>D</given-names></name><name><surname>Marie</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><issue>23</issue><fpage>7896</fpage><lpage>7902</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0795</pub-id></citation><citation citation-type="display-unstructured">Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP et al (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10(23):7896&#x02013;7902 <pub-id pub-id-type="pmid">15585622</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>E</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name></person-group><article-title>Nonparametric estimation from incomplete observations</article-title><source>J Am Stat Assoc</source><year>1958</year><volume>53</volume><fpage>457</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.2307/2281868</pub-id></citation><citation citation-type="display-unstructured">Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457&#x02013;481 </citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mantel</surname><given-names>N</given-names></name></person-group><article-title>Evaluation of survival data and two new rank order statistics arising in its consideration</article-title><source>Cancer Chemother Rep</source><year>1966</year><volume>50</volume><issue>3</issue><fpage>163</fpage><lpage>170</lpage></citation><citation citation-type="display-unstructured">Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50(3):163&#x02013;170 <pub-id pub-id-type="pmid">5910392</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname><given-names>B</given-names></name><name><surname>Heuvel-Eibrink</surname><given-names>MM</given-names></name><name><surname>Schaik</surname><given-names>RH</given-names></name><name><surname>Heiden</surname><given-names>IP</given-names></name><name><surname>Wiemer</surname><given-names>EA</given-names></name><name><surname>Vossebeld</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients</article-title><source>Clin Pharmacol Ther</source><year>2006</year><volume>80</volume><issue>5</issue><fpage>427</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2006.07.005</pub-id></citation><citation citation-type="display-unstructured">van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, van der Heiden IP, Wiemer EA, Vossebeld PJ et al (2006) ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther 80(5):427&#x02013;439 <pub-id pub-id-type="pmid">17112800</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suvannasankha</surname><given-names>A</given-names></name><name><surname>Minderman</surname><given-names>H</given-names></name><name><surname>O&#x02019;Loughlin</surname><given-names>KL</given-names></name><name><surname>Nakanishi</surname><given-names>T</given-names></name><name><surname>Ford</surname><given-names>LA</given-names></name><name><surname>Greco</surname><given-names>WR</given-names></name><etal/></person-group><article-title>Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival</article-title><source>Br J Haematol</source><year>2004</year><volume>127</volume><issue>4</issue><fpage>392</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2004.05211.x</pub-id></citation><citation citation-type="display-unstructured">Suvannasankha A, Minderman H, O&#x02019;Loughlin KL, Nakanishi T, Ford LA, Greco WR et al (2004) Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br J Haematol 127(4):392&#x02013;398 <pub-id pub-id-type="pmid">15521915</pub-id></citation></ref><ref id="CR24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Legrand</surname><given-names>O</given-names></name><name><surname>Simonin</surname><given-names>G</given-names></name><name><surname>Zittoun</surname><given-names>R</given-names></name><name><surname>Marie</surname><given-names>JP</given-names></name></person-group><article-title>Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques</article-title><source>Leukemia</source><year>1998</year><volume>12</volume><issue>9</issue><fpage>1367</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2401117</pub-id></citation><citation citation-type="display-unstructured">Legrand O, Simonin G, Zittoun R, Marie JP (1998) Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia 12(9):1367&#x02013;1374 <pub-id pub-id-type="pmid">9737684</pub-id></citation></ref><ref id="CR25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baldus</surname><given-names>C</given-names></name><name><surname>Fietz</surname><given-names>T</given-names></name><name><surname>Rieder</surname><given-names>H</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Thiel</surname><given-names>E</given-names></name><name><surname>Knauf</surname><given-names>W</given-names></name></person-group><article-title>MDR-1 expression and deletions of chromosomes 7 and 5(Q) separately indicate adverse prognosis in AML</article-title><source>Leuk Lymphoma</source><year>2001</year><volume>40</volume><issue>5&#x02013;6</issue><fpage>613</fpage><lpage>623</lpage></citation><citation citation-type="display-unstructured">Baldus C, Fietz T, Rieder H, Schwartz S, Thiel E, Knauf W (2001) MDR-1 expression and deletions of chromosomes 7 and 5(Q) separately indicate adverse prognosis in AML. Leuk Lymphoma 40(5&#x02013;6):613&#x02013;623 <pub-id pub-id-type="pmid">11426533</pub-id></citation></ref><ref id="CR26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filipits</surname><given-names>M</given-names></name><name><surname>Pohl</surname><given-names>G</given-names></name><name><surname>Stranzl</surname><given-names>T</given-names></name><name><surname>Suchomel</surname><given-names>RW</given-names></name><name><surname>Scheper</surname><given-names>RJ</given-names></name><name><surname>Jager</surname><given-names>U</given-names></name><etal/></person-group><article-title>Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia</article-title><source>Blood</source><year>1998</year><volume>91</volume><issue>5</issue><fpage>1508</fpage><lpage>1513</lpage></citation><citation citation-type="display-unstructured">Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jager U et al (1998) Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91(5):1508&#x02013;1513 <pub-id pub-id-type="pmid">9473213</pub-id></citation></ref><ref id="CR27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leith</surname><given-names>CP</given-names></name><name><surname>Kopecky</surname><given-names>KJ</given-names></name><name><surname>Godwin</surname><given-names>J</given-names></name><name><surname>McConnell</surname><given-names>T</given-names></name><name><surname>Slovak</surname><given-names>ML</given-names></name><name><surname>Chen</surname><given-names>IM</given-names></name><etal/></person-group><article-title>Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study</article-title><source>Blood</source><year>1997</year><volume>89</volume><issue>9</issue><fpage>3323</fpage><lpage>3329</lpage></citation><citation citation-type="display-unstructured">Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM et al (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89(9):3323&#x02013;3329 <pub-id pub-id-type="pmid">9129038</pub-id></citation></ref><ref id="CR28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Damiani</surname><given-names>D</given-names></name><name><surname>Tiribelli</surname><given-names>M</given-names></name><name><surname>Calistri</surname><given-names>E</given-names></name><name><surname>Geromin</surname><given-names>A</given-names></name><name><surname>Chiarvesio</surname><given-names>A</given-names></name><name><surname>Michelutti</surname><given-names>A</given-names></name><etal/></person-group><article-title>The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype</article-title><source>Haematologica</source><year>2006</year><volume>91</volume><issue>6</issue><fpage>825</fpage><lpage>828</lpage></citation><citation citation-type="display-unstructured">Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, Michelutti A et al (2006) The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 91(6):825&#x02013;828 <pub-id pub-id-type="pmid">16704962</pub-id></citation></ref><ref id="CR29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steinbach</surname><given-names>D</given-names></name><name><surname>Sell</surname><given-names>W</given-names></name><name><surname>Voigt</surname><given-names>A</given-names></name><name><surname>Hermann</surname><given-names>J</given-names></name><name><surname>Zintl</surname><given-names>F</given-names></name><name><surname>Sauerbrey</surname><given-names>A</given-names></name></person-group><article-title>BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia</article-title><source>Leukemia</source><year>2002</year><volume>16</volume><issue>8</issue><fpage>1443</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2402541</pub-id></citation><citation citation-type="display-unstructured">Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16(8):1443&#x02013;1447 <pub-id pub-id-type="pmid">12145683</pub-id></citation></ref><ref id="CR30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>CS</given-names></name><name><surname>Davidson</surname><given-names>GS</given-names></name><name><surname>Martin</surname><given-names>SB</given-names></name><name><surname>Andries</surname><given-names>E</given-names></name><name><surname>Potter</surname><given-names>J</given-names></name><name><surname>Harvey</surname><given-names>R</given-names></name><etal/></person-group><article-title>Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction</article-title><source>Blood</source><year>2006</year><volume>108</volume><issue>2</issue><fpage>685</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-12-4633</pub-id></citation><citation citation-type="display-unstructured">Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R et al (2006) Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108(2):685&#x02013;696 <pub-id pub-id-type="pmid">16597596</pub-id></citation></ref><ref id="CR31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>BL</given-names></name><name><surname>Colapietro</surname><given-names>AM</given-names></name><name><surname>Barnes</surname><given-names>Y</given-names></name><name><surname>Marini</surname><given-names>F</given-names></name><name><surname>Andreeff</surname><given-names>M</given-names></name><name><surname>Sorrentino</surname><given-names>BP</given-names></name></person-group><article-title>Low levels of ABCG2 expression in adult AML blast samples</article-title><source>Blood</source><year>2002</year><volume>100</volume><issue>13</issue><fpage>4594</fpage><lpage>4601</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-01-0271</pub-id></citation><citation citation-type="display-unstructured">Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP (2002) Low levels of ABCG2 expression in adult AML blast samples. Blood 100(13):4594&#x02013;4601 <pub-id pub-id-type="pmid">12393637</pub-id></citation></ref><ref id="CR32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>BL</given-names></name></person-group><article-title>ABCG2 (BCRP) expression in normal and malignant hematopoietic cells</article-title><source>Hematol Oncol</source><year>2003</year><volume>21</volume><issue>3</issue><fpage>115</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1002/hon.714</pub-id></citation><citation citation-type="display-unstructured">Abbott BL (2003) ABCG2 (BCRP) expression in normal and malignant hematopoietic cells. Hematol Oncol 21(3):115&#x02013;130 <pub-id pub-id-type="pmid">14579240</pub-id></citation></ref><ref id="CR33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Israeli</surname><given-names>D</given-names></name><name><surname>Ziaei</surname><given-names>S</given-names></name><name><surname>Gonin</surname><given-names>P</given-names></name><name><surname>Garcia</surname><given-names>L</given-names></name></person-group><article-title>A proposal for the physiological significance of mdr1 and Bcrp1/Abcg2 gene expression in normal tissue regeneration and after cancer therapy</article-title><source>J Theor Biol</source><year>2005</year><volume>232</volume><issue>1</issue><fpage>41</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2004.07.018</pub-id></citation><citation citation-type="display-unstructured">Israeli D, Ziaei S, Gonin P, Garcia L (2005) A proposal for the physiological significance of mdr1 and Bcrp1/Abcg2 gene expression in normal tissue regeneration and after cancer therapy. J Theor Biol 232(1):41&#x02013;45 <pub-id pub-id-type="pmid">15498591</pub-id></citation></ref><ref id="CR34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Zong</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Sorrentino</surname><given-names>BP</given-names></name></person-group><article-title>Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone</article-title><source>BioTechniques</source><year>2003</year><volume>35</volume><issue>6</issue><fpage>1248</fpage><lpage>1252</lpage></citation><citation citation-type="display-unstructured">Zhou S, Zong Y, Lu T, Sorrentino BP (2003) Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone. BioTechniques 35(6):1248&#x02013;1252 <pub-id pub-id-type="pmid">14682060</pub-id></citation></ref><ref id="CR35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raaijmakers</surname><given-names>MH</given-names></name><name><surname>Grouw</surname><given-names>EP</given-names></name><name><surname>Heuver</surname><given-names>LH</given-names></name><name><surname>Reijden</surname><given-names>BA</given-names></name><name><surname>Jansen</surname><given-names>JH</given-names></name><name><surname>Scheper</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Breast cancer resistance protein in drug resistance of primitive CD34+38-cells in acute myeloid leukemia</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><issue>6</issue><fpage>2436</fpage><lpage>2444</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0212</pub-id></citation><citation citation-type="display-unstructured">Raaijmakers MH, de Grouw EP, Heuver LH, van der Reijden BA, Jansen JH, Scheper RJ et al (2005) Breast cancer resistance protein in drug resistance of primitive CD34+38-cells in acute myeloid leukemia. Clin Cancer Res 11(6):2436&#x02013;2444 <pub-id pub-id-type="pmid">15788695</pub-id></citation></ref><ref id="CR36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goodell</surname><given-names>MA</given-names></name><name><surname>Rosenzweig</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Marks</surname><given-names>DF</given-names></name><name><surname>DeMaria</surname><given-names>M</given-names></name><name><surname>Paradis</surname><given-names>G</given-names></name><etal/></person-group><article-title>Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species</article-title><source>Nat Med</source><year>1997</year><volume>3</volume><issue>12</issue><fpage>1337</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1038/nm1297-1337</pub-id></citation><citation citation-type="display-unstructured">Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, Paradis G et al (1997) Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 3(12):1337&#x02013;1345 <pub-id pub-id-type="pmid">9396603</pub-id></citation></ref><ref id="CR37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>DD</given-names></name></person-group><article-title>Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome</article-title><source>Best Pract Res Clin Haematol</source><year>2004</year><volume>17</volume><issue>4</issue><fpage>641</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1016/j.beha.2004.08.014</pub-id></citation><citation citation-type="display-unstructured">Ross DD (2004) Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol 17(4):641&#x02013;651 <pub-id pub-id-type="pmid">15494300</pub-id></citation></ref></ref-list></back></article> 